Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Status:
RECRUITING
Trial end date:
2035-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.